Cue Biopharma, Inc. Financing Cash Flow
Cue Biopharma, Inc. (CUE) reported Financing Cash Flow of $30.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Cue Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $30.02M, a 68.65% increase year-over-year.
- Cue Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $306.00K.
- Cue Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $9.49M.
- Cue Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.00K, a 99.99% decline year-over-year.
- Cue Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $26.29M, a 156.67% increase from fiscal 2024.
- Cue Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $10.24M, a 13.63% decline from fiscal 2023.
- Cue Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $11.86M, a 77.90% decline from fiscal 2022.
- Cue Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $53.66M, a 178.99% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $30.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $30.32M 10-Q · filed 2026-08-14 | $39.81M derived: sum of 3 quarters · filed 2026-08-14 | $39.82M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $306.00K 10-Q · filed 2026-05-14 | $9.80M derived: sum of 2 quarters · filed 2026-05-14 | $9.80M derived: sum of 3 quarters · filed 2026-05-14 | $27.60M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $9.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $9.49M derived: sum of 2 quarters · filed 2026-03-16 | $27.29M derived: sum of 3 quarters · filed 2026-08-14 | $26.29M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $17.80M derived: sum of 2 quarters · filed 2026-08-14 | $16.80M 10-Q · filed 2025-11-12 | $15.87M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $17.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $16.80M 10-Q · filed 2026-08-14 | $15.87M derived: sum of 3 quarters · filed 2026-08-14 | $25.69M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$1.00M 10-Q · filed 2026-05-14 | -$1.93M derived: sum of 2 quarters · filed 2026-05-14 | $7.89M derived: sum of 3 quarters · filed 2026-05-14 | $6.89M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$932.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.89M derived: sum of 2 quarters · filed 2026-03-16 | $7.89M derived: sum of 3 quarters · filed 2026-03-16 | $10.24M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $9.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $8.82M derived: sum of 2 quarters · filed 2025-11-12 | $11.18M 10-Q · filed 2025-11-12 | $15.96M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.35M 10-Q · filed 2025-08-12 | $6.14M derived: sum of 3 quarters · filed 2025-08-12 | $10.72M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $2.35M 10-Q · filed 2025-05-12 | $7.14M derived: sum of 2 quarters · filed 2025-05-12 | $11.72M derived: sum of 3 quarters · filed 2025-05-12 | $13.83M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $9.37M derived: sum of 2 quarters · filed 2025-03-31 | $11.47M derived: sum of 3 quarters · filed 2025-03-31 | $11.86M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $4.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $6.69M derived: sum of 2 quarters · filed 2024-11-14 | $7.08M 10-Q · filed 2024-11-14 | $34.48M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.49M 10-Q · filed 2024-08-14 | $29.89M derived: sum of 3 quarters · filed 2024-08-14 | $29.88M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $388.00K 10-Q · filed 2024-05-09 | $27.79M derived: sum of 2 quarters · filed 2024-05-09 | $27.78M derived: sum of 3 quarters · filed 2024-05-09 | $38.89M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $27.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $27.39M derived: sum of 2 quarters · filed 2024-03-28 | $38.50M derived: sum of 3 quarters · filed 2024-03-28 | $53.66M 10-K · filed 2024-03-28 | $53.66M 10-K · filed 2023-03-21 |
| 2022-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $11.10M derived: sum of 2 quarters · filed 2023-11-03 | $26.26M 10-Q · filed 2023-11-03 | $33.64M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $11.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $26.27M 10-Q · filed 2023-08-08 | $33.65M derived: sum of 3 quarters · filed 2023-08-08 | $34.00M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $15.16M 10-Q · filed 2023-05-09 | $22.54M derived: sum of 2 quarters · filed 2023-05-09 | $22.89M derived: sum of 3 quarters · filed 2023-05-09 | $33.56M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $7.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $7.73M derived: sum of 2 quarters · filed 2023-03-21 | $18.40M derived: sum of 3 quarters · filed 2023-03-21 | $19.23M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $351.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $11.02M derived: sum of 2 quarters · filed 2022-11-14 | $11.85M 10-Q · filed 2022-11-14 | $12.10M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $10.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $11.50M 10-Q · filed 2022-08-04 | $11.74M derived: sum of 3 quarters · filed 2022-08-04 | $26.76M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $834.00K 10-Q · filed 2022-05-10 | $1.08M derived: sum of 2 quarters · filed 2022-05-10 | $16.09M derived: sum of 3 quarters · filed 2022-05-10 | $59.41M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $244.26K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $15.26M derived: sum of 2 quarters · filed 2022-03-16 | $58.58M derived: sum of 3 quarters · filed 2022-03-16 | $58.61M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $15.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $58.33M derived: sum of 2 quarters · filed 2021-11-09 | $58.37M 10-Q · filed 2021-11-09 | $92.86M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $43.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $43.36M 10-Q · filed 2021-08-09 | $77.85M derived: sum of 3 quarters · filed 2021-08-09 | $90.14M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $36.00K 10-Q · filed 2021-05-10 | $34.53M derived: sum of 2 quarters · filed 2021-05-10 | $46.82M derived: sum of 3 quarters · filed 2021-05-10 | $50.57M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $34.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $46.79M derived: sum of 2 quarters · filed 2021-03-09 | $50.53M derived: sum of 3 quarters · filed 2021-03-09 | $50.79M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $12.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $16.04M derived: sum of 2 quarters · filed 2020-11-09 | $16.30M 10-Q · filed 2020-11-09 | $20.47M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $4.00M 10-Q · filed 2020-08-07 | $8.17M derived: sum of 3 quarters · filed 2020-08-07 | ||
| 2019-03-31 | $257.00K 10-Q · filed 2020-05-07 | $4.43M derived: sum of 2 quarters · filed 2020-05-07 | |||
| 2018-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $4.18M 10-K · filed 2020-03-12 | |||
| 2018-09-30 | $12.00K 10-Q · filed 2019-11-07 | ||||
| 2017-12-31 | $62.05M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $62.03M derived: sum of 2 quarters · filed 2019-03-14 | $62.00M 10-K · filed 2019-03-14 | ||
| 2017-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$44.00K 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | -$22.00K 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |